Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research report released on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

TENX has been the topic of a number of other research reports. William Blair reaffirmed an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. Leerink Partners set a $20.00 price objective on Tenax Therapeutics in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Tenax Therapeutics Stock Up 2.2 %

Shares of TENX opened at $6.57 on Friday. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $7.89. The stock’s 50 day moving average is $6.44 and its two-hundred day moving average is $5.33.

Institutional Investors Weigh In On Tenax Therapeutics

Several institutional investors have recently modified their holdings of TENX. Janus Henderson Group PLC purchased a new stake in shares of Tenax Therapeutics during the 4th quarter worth approximately $1,026,000. Vestal Point Capital LP acquired a new position in shares of Tenax Therapeutics during the 3rd quarter worth approximately $288,000. Stonepine Capital Management LLC acquired a new position in shares of Tenax Therapeutics during the 3rd quarter worth approximately $173,000. Sphera Funds Management LTD. acquired a new position in shares of Tenax Therapeutics during the 3rd quarter worth approximately $101,000. Finally, Millennium Management LLC acquired a new position in shares of Tenax Therapeutics during the 4th quarter worth approximately $166,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.